Article citationsMore>>

Chamuleau, M. (2022) R-CODOX-M/R-IVAC versus Dose-Adjusted (DA)-EPO-CH-R in Patients with Newly Diagnosed High-Risk Burkitt Lymphoma; First Results of a Multi-Center Randomized Hovon/Sakk Trial [Abstract LB2370]. Proceedings of the European Hematology Association Congress EHA2022, Vienna, 9-12 June 2022.

has been cited by the following article:

SCIRP Newsletter
Copyright © 2006-2026 Scientific Research Publishing Inc. All Rights Reserved.
Top